Furthermore, with the growing number of clock-targeting small molecules with CSC-specific toxicity being identified, it may be reasonable to expect that integrating chrono-cancer therapy into future research and clinical trials will improve the treatment and management of multiple cancers linked to CSC evolution. This evidence concerns the gene CLOCK and cancer.